Bristol-Myers says cancer drug met goal in study

Associated Press |

NEW YORK (AP) — Bristol-Myers said Tuesday that its skin cancer drug nivolumab worked in a late-stage clinical trial, leading the drugmaker to end the study early.



Bristol-Myers said patients treated with nivolumab lived longer than patients who received only chemotherapy. The study compared the experimental treatment to an older drug called dacarbazine, and it was designed to evaluate nivolumab as a primary treatment for melanoma, the most dangerous type of skin cancer. Patients in the study had advanced melanoma with a specific genetic mutation.

The company did not report specific results from the trial, which enrolled 418 patients.

Shares of Bristol-Myers Squibb Co. rose $1.15, or 2.4 percent, to $49.45 in aftermarket trading. The stock rose 30 cents to $48.30 during the day.

Nivolumab hasn't yet been approved, but Bristol-Myers Squibb is getting ready to file for approval of the drug as a treatment for non-small cell lung cancer. A drug regimen that combines nivolumab with an approved drug, Yervoy, has also showed promise as a treatment for melanoma.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Companies

Symbol Name Price Change % Volume
ZFPPF Zambeef Product Plc Ord 0.20 0.00 0.00 0

Comments

Emerging Growth

Reliq Health Technologies Inc.

Moseda Technologies Inc provides mobile and IT cloud computing to increase operational efficiency and security. It develops SmartFleet, a solution designed for commercial use, as well as SmartCare, a mHealth…

Private Markets

XY Find It

Founded by serial entrepreneur Arie Trouw, XY Findables follows a single guiding principle: customers should never lose anything important again. With over 50,000 users around the world, more than 100,000…

BioSculpture Technology, Inc.

BioSculpture Technology, Inc. (“BST”) is a commercial-stage medical device manufacturer of liposuction surgical instruments for surgeons. It offers the FDA-cleared Twin Cannula Assisted Liposuction ("TCAL") Airbrush Liposculptor II® controllers, Airbrush®…